Lytix Biopharma
Lytix Biopharma: Redeye Resumes Coverage (Redeye)

2024-04-26 15:08
Through the completion of the equity issue, Lytix receives NOK50m before transaction costs. The issue was almost fully subscribed to the lower amount, with around 5% going to certain pre-committing shareholders and guarantors.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Lytix Biopharma - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -